Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005.
about
Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.Data quality in the Danish National Acute Leukemia Registry: a hematological data resourceTwenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France)Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaIncidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromesSimilarities and differences between therapy-related and elderly acute myeloid leukemia.Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.Familial aggregation of acute myeloid leukemia and myelodysplastic syndromesComparison of different approaches to estimating age standardized net survival.Is obesity a prognostic factor for acute myeloid leukemia outcome?Acute myeloid leukemia in the real world: why population-based registries are needed.Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.Emerging new approaches for the treatment of acute promyelocytic leukemia.Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of lifePatient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemiaHypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.Acute myeloid leukemia in older adults.Vascular endothelial growth factor signaling in acute myeloid leukemia.Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Return to work and work-related disability among AML survivors.Determination of volatile organic compounds exhaled by cell lines derived from hematological malignancies.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program.Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study.Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults.Excess mortality in the myelodysplastic syndromes.Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.Successful haploidentical stem cell transplantation with prophylactic administration of liposomal amphotericin B after invasive pulmonary zygomycosis.Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study.
P2860
Q30490446-6FCB6F42-3A2E-4879-8AD1-46ABE5A8C0E3Q30620658-8E9D41B1-1119-4DDA-9E56-880E499684C4Q30667157-EF090155-E65F-43B0-A81B-D43684B247FFQ33726712-F7934AF4-E4A6-4048-8C05-F629243FB6F8Q33840247-90962CEE-87F0-4AA1-86DC-2B04F0E4D4D4Q35018521-2EBC5517-E46E-4235-9200-8C45CE9F4D8BQ35032345-B01B1189-B9FF-4404-A732-8D9909DDF9E8Q35112049-9F6CFCB5-6C46-4B75-88AA-3751F181C005Q35112330-7ED81A20-DF96-432D-A5FE-765AE62D708BQ35640731-D7CA8E15-7061-4918-A755-023873FB03C7Q35651744-19801F28-93C7-440C-90D9-EB5DB8DFC9B8Q35665103-8D99C1F8-2F17-4E72-9E00-47E8CA984023Q35746703-59A0DD21-02DF-49D3-940E-9F277C10F8B0Q35749864-B584FC2C-6D3B-467C-8CB4-C88C94B01A07Q35980291-3C5ECEAB-F241-422A-93D9-073ED5032D2EQ36157668-9B8775E5-36F8-41B6-9FDD-C3BB3D6DB475Q36554393-0A990850-FC61-44AD-92C1-39CBDB7A0FFEQ36612619-10F83DE3-AC33-4C6F-A662-D0639F17791AQ36633055-0C5EE3A6-2D0D-4365-9BBB-5A8DA8FDED99Q36739522-BB2F260F-E2F8-4B20-B2B1-BEB85F23D879Q36866323-C8CEDF0F-3B6F-4356-99BF-A99B7AF4F25EQ36887700-F3A4D16B-6AEC-4411-97A2-318C4929AC33Q37605585-F68384B6-80C6-444D-97D5-39269FBCC49CQ37701604-539EE722-A69D-4885-BB81-7BC4878CC3D0Q38022075-549D2972-1213-4813-B3CD-DC77B31C1E18Q38026008-0629A248-21DB-43ED-8E76-5083D65B29EDQ38029546-3792B2F3-222F-4E2E-8119-CB5CE5863720Q38213704-FBB6D16D-96E5-43CF-9B76-20E9AE61DD68Q38601723-4A4010B2-B674-411B-B224-DAD58E834DD2Q38624682-D5E3021A-3A66-4E13-B4AD-99740213C8CFQ38703407-B4DE970F-AEA2-46D5-BCBE-291ED53C5373Q38918850-CE3B6DA8-A903-4FE8-9022-5102352FF634Q39002065-B224E575-4D99-4D89-B2D2-E4C922299F41Q39263229-D1CF36B5-8E9C-4494-BEBE-A80F2EE80246Q39449424-EB2C19C7-59FE-44C4-A492-16049B531BC7Q39768527-EA5301BA-485D-44EA-AD38-0E9394272B98Q40470007-5A3BA0F2-560A-4731-8E14-FF0FECE678EDQ40727176-8614393E-13F2-44E6-ABA1-A04C9C821BE3Q40961845-DCBF90AD-787E-4A56-9CE6-CC19C2FE86DBQ41051992-0A3E19FF-4052-41B9-A757-76105DB74D77
P2860
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Improved patient survival for ...... Sweden between 1973 and 2005.
@en
type
label
Improved patient survival for ...... Sweden between 1973 and 2005.
@en
prefLabel
Improved patient survival for ...... Sweden between 1973 and 2005.
@en
P2093
P50
P921
P1433
P1476
Improved patient survival for ...... Sweden between 1973 and 2005.
@en
P2093
Asa Rangert Derolf
Magnus Björkholm
Sigurdur Yngvi Kristinsson
P304
P356
10.1182/BLOOD-2008-09-179341
P407
P577
2008-11-19T00:00:00Z